Largest-ever study of psychedelics could help advance their use in treating mental health disorders

Image Credit: Scientific Frontline

Scientific Frontline: Extended "At a Glance" Summary: Common Neural Mechanisms of Psychedelics

The Core Concept: Despite their distinct chemical compositions, various psychedelic compounds—including psilocybin, LSD, mescaline, DMT, and ayahuasca—produce a unified, common pattern of brain activity.

Key Distinction/Mechanism: The shared neurological effect manifests through two distinct, measurable changes: the weakening of normally tight, highly organized neural networks (reduced intra-network connectivity) and a concurrent increase in communication between brain networks that are usually segregated (increased inter-network cross-talk). This boundary-crossing communication is theorized to drive the atypical perceptions, thoughts, and hallucinations associated with the psychedelic experience.

Origin/History: Following the "psychedelic research winter" of the 1970s characterized by criminalization and stigma, modern advances in brain imaging have fueled a scientific revival. In April 2026, an international consortium led by a McGill University researcher published the largest-ever meta-analysis on the subject in Nature Medicine, pooling 11 global datasets comprising over 500 brain imaging sessions from 267 participants.

Treating Tumors Independently of Oxygen

Johannes Karges and his team have developed a new mechanism of activity against cancer cells.
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Hypoxic Photodynamic Therapy

The Core Concept: A novel photodynamic therapy (PDT) approach utilizing a ruthenium-based active agent to effectively destroy cancer cells even within severe, oxygen-depleted (hypoxic) tumor environments.

Key Distinction/Mechanism: Traditional photodynamic cancer treatments rely on the presence of ambient oxygen to create cell-killing reactive oxygen species, making them largely ineffective in the oxygen-starved centers of fast-growing tumors. This newly developed therapy circumvents the need for molecular oxygen entirely. When oxygen is absent, intracellular iron coordinates with the active agent, triggering an ultra-fast metal-to-metal electron transfer from the excited ruthenium center to the iron center. This process converts naturally occurring hydrogen peroxide within the cell into highly lethal hydroxyl radicals, which cause fatal oxidative damage to the cancer cells.

Major Frameworks/Components:

• Photodynamic Therapy (PDT): An established cancer treatment method where an administered, inactive substance is activated via targeted light irradiation.
• Ruthenium-Based Active Agent (Ru(II) Polypyridine–Deferasirox Conjugate): The light-activated compound capable of entering an excited electronic state to drive the reaction.
• Metal-to-Metal Electron Transfer: The alternate, oxygen-independent chemical pathway where electrons transfer from the ruthenium center to an iron center.
• Hydroxyl Radicals: Highly reactive, cell-destroying molecules generated by the conversion of cellular hydrogen peroxide during the electron transfer process.

Researchers find way to treat lung cancer and associated muscle wasting at the same time

Illustration shows depicts treating lung tumors with lipid nanoparticles loaded with follistatin.
Image Credit: Parinaz Ghanbari

Scientific Frontline: Extended "At a Glance" Summary: Dual-Targeted mRNA Therapy for Lung Cancer and Cachexia

The Core Concept: This novel therapeutic approach utilizes specialized lipid nanoparticles (LNPs) to deliver follistatin messenger RNA (mRNA) directly to lung tumors, simultaneously inhibiting cancer growth and reversing cachexia, a severe muscle-wasting syndrome.

Key Distinction/Mechanism: Unlike conventional LNPs, which typically accumulate in the liver following systemic administration, these modified LNPs bind to the blood serum protein vitronectin. The vitronectin directs the LNPs specifically to lung cancer tumors by interacting with integrin receptors that are overexpressed on the tumor surface. Once absorbed, the mRNA instructs the cells to produce follistatin, a protein known to suppress tumor progression and stimulate muscle tissue growth.

Major Frameworks/Components: 

• Lipid Nanoparticles (LNPs): Nanoscale delivery vehicles composed of fatty acids designed to carry genetic material intravenously without degrading.
• Follistatin mRNA: The therapeutic genetic payload that triggers the endogenous production of the dual-action follistatin protein.
• Vitronectin: A naturally occurring blood serum protein that binds to the LNPs and acts as a homing beacon.
• Integrin Receptors: Surface receptors overexpressed on lung cancer cells that interact with vitronectin to facilitate the precise cellular uptake of the LNPs.

Electroacupuncture shows promise in breast cancer survivors

“Patients often report feeling unprepared for the cognitive and emotional challenges that persist after treatment,” says the study’s corresponding author, Alexandre Chan, UC Irvine professor and founding chair of the Department of Clinical Pharmacy Practice. “We need robust scientific evidence to show how effective interventions can be integrated into their treatment in order to reduce survivors’ symptoms and improve their healing journeys.”
Photo Credit: Steve Zylius / UC Irvine

Scientific Frontline: Extended "At a Glance" Summary: Electroacupuncture in Post-Cancer Care

The Core Concept: Electroacupuncture is an integrative, non-pharmacological therapy that applies a mild electrical current to traditional acupuncture needles. It is utilized to improve persistent cognitive dysfunction and reduce psychological distress in breast cancer survivors.

Key Distinction/Mechanism: Unlike traditional acupuncture, electroacupuncture introduces mild electrical stimulation to targeted neuropsychiatric-specific acupoints. This localized approach has been shown to increase gray matter volume, improve brain network connectivity, and reduce blood-based biomarkers associated with neuroinflammation, offering a distinct alternative to symptom-management medications that carry dependency and interaction risks.

Major Frameworks/Components:

• Targeted Acupoint Stimulation: Focusing electrical stimulation on specific neuro-psychological functional points rather than non-specific control points.
• Neuroimaging Assessments: Utilizing brain imaging to track physical changes in gray matter volume and functional neural connectivity.
• Biomarker Analysis: Measuring blood-based markers to directly quantify reductions in systemic neuroinflammation.
• Cognitive and Psychological Testing: Quantifying measurable enhancements in attention and reductions in clinical distress.

Scalable cell imaging method could help make drug safety testing faster, cheaper

Human liver cells treated with a cancer drug are imaged under a microscope using a method called Cell Painting.
Image Credit: Axiom Bio 

Scientific Frontline: Extended "At a Glance" Summary: Cell Painting for Drug Safety Testing

The Core Concept: Cell Painting is a scalable, image-based cellular profiling method that utilizes fluorescent dyes and artificial intelligence to measure thousands of molecular and structural changes in human cells following chemical exposure.

Key Distinction/Mechanism: Unlike conventional cell-based toxicity tests that typically measure single endpoints, Cell Painting labels eight different cellular components and leverages a trained AI model to simultaneously analyze thousands of morphological changes. This high-content approach allows researchers to detect cellular harm—including specifically which proteins and biochemical pathways are affected—at much lower chemical concentrations and with significantly greater detail than traditional assays.

Major Frameworks/Components: 

• Fluorescent Multiplexing: The application of specific dyes to visualize eight distinct cellular compartments and structures simultaneously under a microscope.
• High-Throughput Image Analysis: Culturing human primary cells (such as liver cells), exposing them to over 1,000 different chemicals at varying concentrations, and capturing the resulting morphological data.
• Artificial Intelligence and Machine Learning: The deployment of predictive computational models trained on extensive cell-based toxicity datasets to recognize biological signatures indicative of adverse effects.

Common Disinfectant Chemicals Far More Toxic When Inhaled

Researchers at UC Davis found in a mouse study that chemicals commonly found in disinfectant sprays may be more harmful than once thought.
Photo Credit: Towfiqu Barbhuiya

Scientific Frontline: Extended "At a Glance" Summary: Inhaled Quaternary Ammonium Compounds (QACs) Toxicity

The Core Concept: Inhaling common disinfectant chemicals known as quaternary ammonium compounds (QACs) is profoundly more toxic than oral ingestion, causing severe lung injury at exposure levels frequently found in humans.

Key Distinction/Mechanism: Unlike oral or dermal exposure, where QACs do not efficiently penetrate the gut or skin, inhalation via aerosolized sprays provides a direct pathway into the bloodstream. Once inhaled, these compounds cause 100-fold more lung damage and lethality compared to ingestion, largely by impairing mitochondrial energy production within the cells.

Major Frameworks/Components:

• Quaternary Ammonium Compounds (QACs): The primary active chemical agents found in disinfectant sprays, herbicides, mouthwashes, and fabric softeners.
• Mitochondrial Dysfunction: The cellular mechanism of toxicity wherein elevated QAC levels in the bloodstream correlate directly with decreased energy output in cellular mitochondria.
• Inhalation Toxicity Modeling: The application of murine (mouse) models to prove that respiratory exposure to QACs yields blood chemical concentrations mirroring human exposure levels, resulting in acute pulmonary injury.

Copper Overload Kills Cancer Cells

Johannes Karges is researching compounds that kill tumor cells.
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Light-Activated Cuproptosis in Cancer Treatment

The Core Concept: Cuproptosis is a specific form of cell death triggered by an excess of intracellular copper. Utilizing this mechanism, researchers have developed a light-activated, copper-based agent complex embedded in polymeric nanoparticles that selectively targets and destroys cancer cells while preserving healthy tissue.

Key Distinction/Mechanism: Unlike conventional apoptosis pathways targeted by standard chemotherapy, cuproptosis is triggered when excess copper binds to mitochondrial proteins responsible for energy production, causing them to clump and inducing fatal cellular stress. To prevent damage to healthy cells, the highly toxic copper complex is encapsulated in polymeric nanoparticles that accumulate in tumors; a localized light stimulus is then used to sever a photo-responsive bond, selectively releasing the copper agent exclusively within the malignant tissue.

Major Frameworks/Components: 

• Targeted Metabolic Disruption: Exploits the altered, highly active metabolism of cancer cells, which naturally intake higher levels of copper compared to healthy tissue.
• Polymeric Nanoparticle Encapsulation: A specialized carrier system that safely transports the copper agent complex, preventing premature or uncontrolled release into the bloodstream.
• Photopharmacology and Photoactivated Chemotherapy (PACT): The integration of light-sensitive (photo-responsive) bonds within the basic polymer framework, requiring specific light radiation to dissolve the nanoparticles and achieve localized, highly controlled drug delivery.

Protein modification discovery opens cancer therapy possibilities

Purdue’s W. Andy Tao (front) and his associates have discovered a new type of modification on proteins from cancer-related mutation that holds potential as a therapeutic target. Three members of his group are co- authors of the study published in Nature Chemistry. From left are graduate students Yi-Kai Liu, Zhoujun Luo, and postdoctoral scientist Zheng Zhang.
Photo Credit: Purdue Agricultural Communications / Joshua Clark

Scientific Frontline: "At a Glance" Summary: Protein Modification and Cancer Therapy

• Main Discovery: Researchers identified a novel type of protein modification driven by mutations in the isocitrate dehydrogenase enzyme, which fundamentally alters how kinase enzymes regulate cellular energy and protein function during cancer development.
• Methodology: The research team analyzed normal cells, IDH1 mutant cells, and IDH1 mutant cells treated with anti-cancer drugs using polymer-based metal ion affinity capture to isolate and identify dozens of proteins modified by the metabolite D-2-hydroxyglutarate.
• Key Data: The targeted isocitrate dehydrogenase mutation is prevalent in over 70 percent of specific cancer types, including glioma, acute myeloid leukemia, and rare forms of liver cancer, directly causing an excessive accumulation of D-2-hydroxyglutarate.
• Significance: This study highlights a previously unrecognized chiral-dependent modification where metabolic byproducts exchange chemical signals through phosphorylation crosstalk, exposing a hidden mechanism that fuels tumor progression and metabolic reprogramming in fast-growing cancers.
• Future Application: The identification of these post-translational modifications provides a new framework for precision medicine, enabling the development of targeted therapeutics and advanced diagnostic imaging techniques specifically for cancers driven by isocitrate dehydrogenase mutations.
• Branch of Science: Biochemistry, Oncology, and Molecular Pharmacology.

New compounds to inactivate a key protein in the influenza virus

These new molecules can inhibit neuraminidase, one of the proteins that coats the influenza virus and a key target in many first-line treatments for both seasonal and pandemic influenza.Image Credit:University of Barcelona (NC-ND)

Scientific Frontline: Extended "At a Glance" Summary: Sugar-Derived Aziridines for Influenza Inhibition

The Core Concept: Researchers have designed a novel family of antiviral molecules—sugar-derived aziridines based on the structure of oseltamivir (Tamiflu)—that effectively bind to and inhibit neuraminidase, a key surface protein required for the spread of the influenza virus.

Key Distinction/Mechanism: Unlike current first-line flu treatments which act as reversible inhibitors, these new compounds initially mimic the enzyme’s transition state and subsequently form a covalent chemical bond with a key amino acid in the active site. This creates an irreversible block, permanently deactivating the enzyme and halting viral replication.

Major Frameworks/Components:

• Neuraminidase (NA) Targeting: Focusing on the specific viral surface enzyme responsible for enabling newly formed virus particles to detach from and exit infected host cells.
• Aziridine Ring Substitution: The structural modification of replacing the alkene group in standard oseltamivir with a highly configured aziridine ring to act as the primary reactive agent.
• Covalent Inhibition: The chemical mechanism ensuring permanent deactivation of the viral enzyme, overcoming the limitations and reversibility of traditional antiviral drugs.
• Computational Structural Biology: The utilization of atomic-level 3D modeling and computational methods to observe transition states and design the precise molecular structure of the inhibitors.

Photopharmacology: In-Depth Description

Photopharmacology is an emerging, highly precise branch of medicinal chemistry and pharmacology centered on the design and application of light-responsive drugs. Its primary goal is to achieve unprecedented spatiotemporal control over therapeutic agents. By utilizing specific wavelengths of light to activate or deactivate a drug, photopharmacology allows medical professionals to dictate exactly where in the body a drug acts (spatial control) and exactly when it is active (temporal control). This approach aims to maximize a drug's efficacy at the target site—such as a tumor or a localized infection—while keeping the drug entirely inert in healthy tissues, thereby eliminating severe systemic side effects.

Promising active substance against hepatitis E identified

Researchers have discovered a compound that prevents hepatitis E viruses from replicating. 
Photo Credit: © RUB, Marquard

Scientific Frontline: Extended "At a Glance" Summary: Bemnifosbuvir as a Treatment for Hepatitis E

The Core Concept: Bemnifosbuvir is a synthetic nucleotide/nucleoside analogue, currently in clinical trials for hepatitis C, that has been identified as a highly effective inhibitor of the hepatitis E virus (HEV).

Key Distinction/Mechanism: The drug functions by providing "false building blocks" that mimic the natural structural components of viral genetic material. When the hepatitis E virus attempts to copy its genome, it incorporates these synthetic molecules, which successfully halts viral replication while leaving healthy host cells unharmed.

Major Frameworks/Components:

• Nucleotide/Nucleoside Analogues: The foundational pharmacological framework utilizing synthetic molecules structured similarly to DNA/RNA components to disrupt viral synthesis.
• Fluorescent Reporter Virus Screening: An in vitro screening methodology utilizing a modified virus carrying a fluorescent molecule, allowing researchers to visually monitor and quantify viral replication and its active inhibition.
• Preclinical Validation: The methodological progression from cellular assays to animal models to confirm both the compound's safety profile and its direct efficacy against HEV-induced liver inflammation.

Blood pressure-lowering drug with a light switch

Jörg Standfuss (left) and Quentin Bertrand are two of the researchers in the PSI Center for Life Sciences who now have found out, on the molecular level, why a light-controllable drug changes its potency.
Photo Credit: © Paul Scherrer Institute PSI/Markus Fischer

Scientific Frontline: Extended "At a Glance" Summary: Blood Pressure-Lowering Drug with a Light Switch

The Core Concept: Researchers have developed and observed a light-switchable blood pressure medication that alters its molecular shape and potency when exposed to specific wavelengths of light. This advancement allows the drug's therapeutic effects to be modulated with precise timing and localization within the body.

Key Distinction/Mechanism: Unlike standard beta blockers, the experimental drug photoazolol-1 contains an integrated azobenzene atomic group functioning as a synthetic light switch. When irradiated with violet light, this atomic group flips, changing the molecule from a straight to a bulkier, bent shape. While the molecule remains inside the binding pocket of the β-adrenergic receptor, its altered form binds less effectively, reducing its capacity to block adrenaline and dynamically altering the receptor's activity.

Origin/History: The switchable molecule was synthesized by collaboration partners at the Consejo Superior de Investigaciones Científicas in Barcelona. Its exact molecular transformation mechanisms were subsequently mapped by researchers at the Paul Scherrer Institute (PSI) using the SwissFEL X-ray free-electron laser, with the findings recently published in the journal Angewandte Chemie.

Novel cancer drug delivery system improves Paclitaxel absorption

Paclitaxel binding to L-PGDS
Improved solubility through hydrophobic bonds and CRGDK targeting peptides.
Image Credit: Osaka Metropolitan University

Scientific Frontline: Extended "At a Glance" Summary: Novel Cancer Drug Delivery System for Paclitaxel

The Core Concept: Researchers have developed a targeted drug delivery system (DDS) that utilizes the lipocalin-type prostaglandin D synthase (L-PGDS) enzyme as a carrier to efficiently solubilize and transport Paclitaxel, a heavy and poorly water-soluble anticancer drug, directly to cancerous tissues.

Key Distinction/Mechanism: Unlike conventional formulations that lose their efficacy shortly after administration ceases, this novel system maintains sustained antitumor effects. It functions by binding Paclitaxel via hydrophobic interactions to the β-barrel structure of the L-PGDS protein, which improves the drug's solubility by approximately 3,600-fold. Furthermore, a specialized targeting peptide (CRGDK) is attached to the protein, directing the drug specifically to neuropilin-1 receptors expressed on the surface of cancer cells rather than distributing it to healthy tissues.

Major Frameworks/Components: 

• Paclitaxel (PTX): An established, heavy-molecular-weight (854 Da) anticancer drug traditionally limited by its poor water solubility.
• L-PGDS Enzyme Carrier: The lipocalin-type prostaglandin D synthase protein used as a structural vehicle to house and transport the drug.
• Hydrophobic Interactions: The chemical mechanism allowing PTX to successfully bind to the upper region of the L-PGDS β-barrel.
• CRGDK Targeting Peptide: A specific peptide sequence attached to the C-terminus of L-PGDS that acts as a homing mechanism for neuropilin-1 receptors on cancer cells.

Researchers design a pioneering drug capable of reversing cognitive decline in Alzheimer’s disease in animal models

The study has been led by researchers from the Faculty of Pharmacy and Food Sciences at the University of Barcelona.
Photo Credit: Courtesy of University of Barcelona

Scientific Frontline: "At a Glance" Summary: Pioneering Drug for Alzheimer's Disease

• Main Discovery: Researchers have developed and validated an experimental compound, FLAV-27, capable of reversing cognitive decline in Alzheimer's disease by reprogramming the neuronal epigenome to correct altered gene expression rather than merely clearing amyloid plaques.
• Methodology: The team administered FLAV-27 to inhibit the G9a enzyme by blocking its access to S-adenosylmethionine, testing the drug's effects on epigenetic regulation across in vitro assays, C. elegans worms, and murine models of both early- and late-onset Alzheimer's disease.
• Key Data: While current monoclonal antibody treatments only slow cognitive decline by 27% to 35%, FLAV-27 restored functional cognition, social behavior, and synaptic structure in animal models while returning elevated peripheral biomarkers, including H3K9me2, SMOC1, and p-tau181, to normal baseline levels.
• Significance: The findings confirm that epigenetic dysregulation is a controllable mechanism linking major Alzheimer's pathologies such as neuroinflammation and tau accumulation, establishing a foundation for a new class of epigenetic disease-modifying therapies.
• Future Application: The compound will advance toward human clinical trials through regulatory toxicology studies, utilizing identified blood biomarkers to efficiently screen suitable patients and objectively monitor therapeutic efficacy via routine blood tests.
• Branch of Science: Neuropharmacology, Epigenetics, and Neuroscience.

Antibiotics can affect the gut microbiome for several years

Researchers have now collected a second sample from nearly half of the participants. The analyses are expected to reveal which effects remain after 16 years.
Photo Credit: Sandra Gunnarsson

Scientific Frontline: Extended "At a Glance" Summary: Long-Term Antibiotic Impact on the Gut Microbiome

The Core Concept: Antibiotic treatments can alter the composition and diversity of the bacterial community in the gastrointestinal tract, known as the gut microbiome, with measurable disruptions persisting for four to eight years after a single course of treatment.

Key Distinction/Mechanism: While the short-term disruptive effects of antibiotics on gut flora are well-documented, this research establishes the protracted nature of this ecological footprint. The mechanism of disruption varies significantly by antibiotic class; drugs such as clindamycin, fluoroquinolones, and the narrow-spectrum flucloxacillin cause substantial, long-lasting decreases in bacterial diversity, whereas commonly prescribed options like penicillin V result in only minor, transient changes.

Major Frameworks/Components: 

• Epidemiological Data Linkage: The methodology relies on cross-referencing longitudinal, individual-level pharmacy dispensing data with large-scale biobank microbiome mapping (utilizing Swedish population-based cohorts like SCAPIS and SIMPLER).
• Bacterial Diversity Reduction: The core metric for microbiome health in the study is the quantifiable decrease in the diversity of bacterial species present in the gut following exposure to specific antimicrobials.
• Antibiotic Stratification: The framework evaluates post-treatment recovery times by differentiating the ecological impact based on the specific spectrum and chemical class of the antibiotic administered.

New therapy approach for Leigh Syndrome

Microscopic image of a 3D brain model, as used in the study
(red: neural progenitor cells; blue: neurons).
Image Credit: © HHU / Stephanie Le, AG Prigione

Scientific Frontline: "At a Glance" Summary: Sildenafil as a Therapy for Leigh Syndrome

• Main Discovery: Researchers identified the repurposed drug Sildenafil as a highly promising and effective treatment capable of improving the disease course of Leigh Syndrome, a severe and previously untreatable mitochondrial disorder affecting brain energy metabolism.
• Methodology: The international research consortium derived induced pluripotent stem cells from patient skin cells to cultivate 3D brain organoids and nerve networks, subsequently utilizing these models to screen a comprehensive library of over 5,500 approved drugs and molecules.
• Key Data: Affecting roughly one in 36,000 live births, Leigh Syndrome had no approved treatments until this study screened 5,500 compounds and successfully administered the leading candidate, Sildenafil, to six human patients, all of whom demonstrated rapid recovery from critical episodes and increased muscular strength.
• Significance: Because Sildenafil already possesses a well-documented long-term safety profile for treating pulmonary hypertension in infants, this discovery bypasses standard early-phase toxicity hurdles, offering an immediate and safe therapeutic intervention for a fatal childhood neurodevelopmental disease.
• Future Application: The European Medicines Agency has officially granted Sildenafil an Orphan Drug Designation, enabling the SIMPATHIC research consortium to initiate a multinational, placebo-controlled clinical trial aimed at securing formal regulatory approval for widespread clinical use.
• Branch of Science: Pediatric Neurology, Cellular Biology, and Molecular Pharmacology.
• Additional Detail: The study represents the largest drug screening process ever conducted specifically for Leigh Syndrome, successfully overcoming the traditional lack of accurate cellular and animal models that historically hindered rare disease research.

Gene-based therapies poised for major upgrade thanks to Oregon State University research

Graphic depicts nanoparticles loaded with a genetic therapy entering a cell.
Image Credit: Courtesy of Oregon State University

Scientific Frontline: Extended "At a Glance" Summary: Advanced Lipid Nanoparticles for Gene Therapy

The Core Concept: A novel drug delivery methodology that utilizes optimized lipid nanoparticles to successfully transport genetic therapies and gene-editing tools into targeted sub-cellular compartments without being destroyed by the cell's natural waste disposal systems.

Key Distinction/Mechanism: Traditionally, many gene therapies are intercepted by lysosomes (the cell's recycling centers) and degraded before they can function. This new approach utilizes advanced ionizable lipids—which change their charge state depending on surrounding acidity—and a pioneering DNA-based barcoding system to measure, design, and select nanoparticle carriers that efficiently evade cellular destruction to release their genetic cargo.

Origin/History: The breakthrough findings were published in Nature Biotechnology on March 11, 2026. The research was spearheaded by graduate student Antony Jozić under the guidance of Professor Gaurav Sahay at the Oregon State University College of Pharmacy, in collaboration with researchers from OHSU, Tennessee Technological University, Yeungnam University (South Korea), and the University of Brest (France).

Medicinal cannabis may offer relief for endometriosis and pelvic pain

Photo Credit: Jeff W

Scientific Frontline: "At a Glance" Summary: Medicinal Cannabis for Endometriosis and Pelvic Pain

• Main Discovery: Cannabidiol oil, used alone or combined with dried cannabis flower, effectively reduces pain, improves sleep quality, and lowers anxiety in individuals suffering from endometriosis and related pelvic pain.
• Methodology: Researchers conducted a three-month prospective observational cohort study involving 28 participants diagnosed with endometriosis and/or pelvic pain. Participants were prescribed cannabidiol oil or a combination of the oil and dried cannabis flower, recording weekly pain scores on a 0-to-10 numerical scale and completing health profile questionnaires before and after the 12-week trial.
• Key Data: Overall pelvic pain scores decreased from an average of 5.4 to 3.7 out of 10. The severity of the worst pain experienced by participants dropped from an average of 7.6 to 5.3 out of 10, marking a clinically meaningful improvement in health-related quality of life.
• Significance: The study provides evidence for a well-tolerated, non-opioid alternative for managing complex endometriosis symptoms. The secondary benefits of reduced anxiety and improved sleep contributed to patient quality of life as significantly as the direct reduction in physical pain.
• Future Application: Large-scale clinical trials are required to establish standardized dosing, evaluate long-term safety, and identify specific patient profiles that will benefit most from medicinal cannabis as a primary or adjunct therapy for inflammatory pelvic conditions.
• Branch of Science: Gynecology and Pharmacology.
• Additional Detail: Participants reported that medicinal cannabis presented fewer and more manageable side effects compared to traditional opioid-based analgesics like tramadol, which frequently caused nausea, dizziness, and fatigue without providing consistent pain relief.

Early Alzheimer's increased connectivity lowered by cancer drug in the lab

Neurons exposed to amyloid-beta formed more connections (SSBs = single synaptic boutons), which could be lessened with cancer drug eFT508.
Image Credit: Figure reproduced from Wu et al. 2026

Scientific Frontline: Extended "At a Glance" Summary: Early Alzheimer's Hyperconnectivity and eFT508

The Core Concept: In the earliest stages of Alzheimer's disease, typically correlating with Mild Cognitive Impairment (MCI), low levels of the amyloid-beta protein induce an abnormal increase in neural connections (hyperconnectivity) prior to widespread cell death and memory loss.

Key Distinction/Mechanism: Challenging the traditional model that Alzheimer's begins primarily with synapse loss, this research demonstrates that the disease may actually initiate with too many poorly organized connections. Amyloid-beta rewires, rather than simply increases or decreases, cellular protein production, pushing neurons into an unstable state. The experimental cancer drug eFT508, which targets MAP kinase interacting kinase (MNK), successfully prevented this hyperconnectivity and restored normalized protein production in laboratory models.

Major Frameworks/Components:

• Amyloid-Beta Induced Synaptogenesis: Exposure to low doses of amyloid-beta over a short five-day period triggers hyperconnectivity and creates a self-reinforcing loop by upregulating the amyloid precursor protein.
• Expansion Microscopy: A state-of-the-art imaging technique that expands biological samples 5 to 6 times, enabling researchers to visualize and quantify individual synapses as small as 30 nanometers.
• Liquid-Chromatography Mass-Spectrometry: An analytical method used to profile internal neuronal changes, identifying 49 specific proteins whose production was altered by amyloid-beta exposure.
• MNK Inhibition (eFT508): The pharmacological mechanism utilized by the repurposed cancer drug to decrease neuroinflammation, inhibit abnormal protein synthesis, and restore approximately 70% of altered protein production.

Relax study by Dresden scientists: Innovative combination therapy shows promising efficacy in aggressive leukemia

Alongside his colleague Dr. Leo Ruhnke (right side), Prof. Christoph Röllig (left side) designed and supervised the RELAX study
Photo Credit: Courtesy of Dresden University

Scientific Frontline: "At a Glance" Summary: Acute Myeloid Leukemia Combination Therapy

• Main Discovery: The addition of the BCL2 inhibitor venetoclax to intensive chemotherapy substantially improves treatment outcomes for patients suffering from relapsed or refractory acute myeloid leukemia.
• Methodology: Researchers conducted a multicenter phase 1/2 clinical trial known as the RELAX study to evaluate the tolerability and efficacy of combining a standard chemotherapy regimen of cytarabine and mitoxantrone with venetoclax.
• Key Data: The experimental combination therapy achieved a 75 percent complete remission rate, representing a stark increase over the 40 percent remission rate historically observed with conventional chemotherapy alone.
• Significance: By effectively suppressing rapidly growing leukemia cells, this therapeutic approach successfully qualifies a significantly larger proportion of treatment-resistant patients for potentially curative stem cell transplantations.
• Future Application: The treatment regimen is currently undergoing expanded evaluation in over 150 additional patients and demonstrates strong potential to become the new standard of care for treating acute myeloid leukemia relapses.
• Branch of Science: Hematology, Oncology, and Clinical Pharmacology.
• Additional Detail: The therapeutic combination maintained high efficacy even against particularly resistant genetic variants of the disease, with the foundational findings formally published in The Lancet Haematology.